FY2024 EPS Estimates for Precigen Increased by HC Wainwright

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities research analysts at HC Wainwright increased their FY2024 earnings estimates for Precigen in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn ($0.30) per share for the year, up from their prior forecast of ($0.33). HC Wainwright has a "Buy" rating and a $6.00 price objective on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.33) per share. HC Wainwright also issued estimates for Precigen's Q4 2024 earnings at ($0.04) EPS, Q1 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.19) EPS.

Separately, JMP Securities restated a "market outperform" rating and set a $5.00 price target on shares of Precigen in a research note on Tuesday, January 14th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat, Precigen presently has a consensus rating of "Hold" and an average target price of $7.00.

Precigen Price Performance

Shares of NASDAQ PGEN traded down $0.11 during mid-day trading on Monday, hitting $1.29. The company had a trading volume of 1,308,749 shares, compared to its average volume of 2,230,159. The business's 50-day simple moving average is $0.94 and its 200-day simple moving average is $1.05. Precigen has a 12 month low of $0.65 and a 12 month high of $1.93. The firm has a market cap of $376.34 million, a P/E ratio of -2.34 and a beta of 1.65.

Institutional Trading of Precigen

A number of hedge funds and other institutional investors have recently modified their holdings of PGEN. Traphagen Investment Advisors LLC bought a new position in Precigen in the third quarter valued at approximately $29,000. Stifel Financial Corp lifted its position in Precigen by 94.9% in the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 15,680 shares in the last quarter. SG Americas Securities LLC lifted its position in Precigen by 44.2% in the 3rd quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company's stock valued at $43,000 after acquiring an additional 13,823 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in Precigen by 86.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company's stock valued at $52,000 after buying an additional 25,681 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in Precigen by 56.7% in the 2nd quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company's stock valued at $79,000 after buying an additional 18,097 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company's stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.